02 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Tianyin Pharmaceutical, a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), has completed the construction of Qionglai Facility (QLF).
The construction of QLF was completed in mid April as previously projected, which was immediately followed by equipment installation and a series of procedures that prepares the plant for the final GMP certification. The company is aiming for GMP certification process initiation for the QLF TCM pre-extraction facility to begin by mid June.
The pre-extraction facility will conduct initial processing of TCM raw material, separation using alcohol or water precipitation, filtration, centrifugation, concentration and purification of TCM pharmaceutical ingredients which will be further processed for the production of mTCM at the formulation facility.
In preparation for the new GMP standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities in compliance with the new GMP standards. Due to the redesigning of the industrial parks in the suburbs of Chengdu, TPI's manufacturing facility at the Longquan district, east of Chengdu, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for pharmaceutical industry.
The QLF is approximately 18 miles from the company's recently completed Jiangchuan macrolide (JCM) facility. The proposed relocation project also includes our TCM pre-extraction plant which is located near the center of Chengdu surrounded by rapidly expanding residential area. The QLF is estimated to be 80 mu or 53,000 square meters. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities.